• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

AstraZeneca's flagship Tagrisso helps lung cancer patients live longer in pivotal study

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 09, 2019 at 10:42: AM
via AstraZeneca is off to a good start in August. After its PARP inhibitor Lynparza scored in a prostate cancer trial earlier this week, the British drugmaker on Friday disclosed that its star cancer drug Tagrisso helped patients with a certain type of lung cancer live longer in a late-stage study.

article source
 

<



Similar threads

cafead
AstraZeneca&#039;s experimental drug disappoints in breast cancer survival trial
Replies
0
Views
6
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
With FDA nod, AstraZeneca&#039;s FluMist becomes first self-administered flu vaccine
Replies
0
Views
19
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca steps out from Daiichi&#039;s shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Replies
0
Views
28
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: AstraZeneca&#039;s Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
Replies
0
Views
24
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Relay races toward pivotal trial as breast cancer data tee up clash with AstraZeneca&#039;s Truqap
Replies
0
Views
37
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote